Previous work has also shown that there is a relationship between the characteristics of rheumatoid synovial tissue and arthritis activity. The importance of evaluation of synovial tissue samples after experimental treatment has been underscored by the observation that clinical signs and symptoms of arthritis are associated with histological signs of synovitis after treatment of rheumatoid arthritis patients with the monoclonal antibody alemtuzumab, despite profound depletion of circulating lymphocytes. Similarly, rituximab treatment leads to a rapid and significant decrease in synovial B cell numbers in only a subset of rheumatoid arthritis patients, whereas circulating B cells are completely depleted in nearly all patients. Collectively, there is now consistent evidence indicating that analyses of serial biopsy samples can be used as a screening method to test new drug candidates with high sensitivity to change. The absence of changes after treatment would suggest that the therapy is probably not effective, even when only relatively small numbers of subjects have been tested. In contrast, the demonstration of biologic changes in the synovium could provide the rationale for larger, placebo-controlled trials. Most of the synovial biopsy studies have been performed in rheumatoid arthritis patients, but the same approach could be used for the evaluation of novel therapies in patients with . Decreased disease activity after effective treatment has consistently been associated with a reduction of the number of synovial sublining macrophages across different therapies. This attractive approach can be used during early drug development for screening proposes, supporting which new treatments have higher probability to be beneficial in a large scale clinical trial.
Drs. Appels and Braun emphasize in Chapter 4 the importance of the entheses as a site primarily involved in the peripheral and axial inflammation found in patients with spondyloarthritides and describe the features of the synovium in these conditions. The group of spondyloarthritides comprise ankylosing spondylitis, psoriatic arthritis, reactive arthritis, arthritis associated with chronic inflammatory bowel disease and undifferentiated spondyloarthritis. Next, Chapter 5 describes the synovial tissue response to treatment of patients with peripheral spondyloarthritis (Paramarta et al.) . Although data are mainly confined to the effects of TNF inhibition, initial studies suggest that the study of serial synovial biopsies could also be used in spondyloarthritis to distinguish between effective and ineffective treatments. Most studies using serial biopsy in spondyloarthritis have been conducted in psoriatic arthritis, which is discussed in more detail by Drs. Codullo and McInnes in Chapter 6. In this condition, serial skin biopsy can be evaluated as well.
Collectively, analysis of molecular markers in synovial tissue is increasingly used to provide insight into the pathogenesis and to provide proof of mechanism during early drug development. Tissue specificity is not a problem, and examination of serial biopsy samples may be used to monitor the response in individual patients and screen for interesting biologic effects at the site of inflammation. It can be anticipated that future development will include the use of more extensive markers of synovial inflammation and joint degradation and the use of panels of biomarkers in synovial tissue samples.
